Actualités et communiqués de presse Polyrizon 2026 | PLRZ | ISIN IL0011814113

Actualités Eulerpool Polyrizon

Actualités de l'action Polyrizon

Polyrizon est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Polyrizon.

17 mars·
Benzinga
Polyrizon Signs Deal With Contract Research Organization To Carry Out Package Of Preclinical Biocompatibility Studies In Accordance With ISO 10993 Standards, GLP Requirements
10 mars·
Benzinga
Polyrizon Announces Production Of Good Manufacturing Practice Batch Of Clinical Trial Material For Its Lead Product Candidate
26 février·
Yahoo
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
26 février·
Benzinga
Polyrizon Announces Results From Comparative Study Evaluating Regional Nasal Deposition Profile Of Naloxone Formulation Versus Commercial Reference Product
17 février·
Yahoo
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
13 février·
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
10 février·
Yahoo
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
6 février·
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
6 février·
Yahoo
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
6 février·
Benzinga
Clearmind Engages Polyrizon To Apply Proprietary Intranasal Hydrogel Technology To Develop Optimized Formulation Of Clearmind's MEAI For Treatment Of Addiction-Related Disorders, Weight Loss And Other CNS Conditions
4 février·
Yahoo
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
29 janvier·
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
22 janvier·
Yahoo
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
14 janvier·
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
13 janvier·
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
13 janvier·
Yahoo
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
13 janvier·
Benzinga
Polyrizon Announced That Its Board Of Directors Has Authorized The Exploration Of Strategic Investment Opportunities In Select Revenue-Generating Assets; Efforts Include Defense, Aviation And AI Assets While Advancing Its Intranasal Medical Pipeline
8 janvier·
Yahoo
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
8 janvier·
Benzinga
Polyrizon Completes Branding Of PL-14 Allergy Blocker As NASARIX, Advancing Commercial Readiness
5 janvier·
Yahoo
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Communiqués de presse relatifs à l'action Polyrizon

Polyrizon publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

Polyrizon News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Polyrizon (PLRZ, ISIN : IL0011814113). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Polyrizon.

Polyrizon Action

Polyrizon Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements.